Multiple clinical trials have defined PD-L1 as a biomarker for PD-1/PD-L1 checkpoint inhibitor treatment in NSCLC, and PD-L1 is expressed in ~50–70% of NSCLC as reported in the previous studie (22–25). The gene discussed is CD274; the disease is non-small cell lung carcinoma.